Here are four updates from gastroenterology companies from the past week:
GI & Endoscopy
Charles Adelmann, MD, of Norwalk, Conn.--based Soundview Medical Associates spoke with Becker's ASC Review about the biggest issues in gastroenterology today.
Landos Biopharma reported results from its phase 1 trial of BT-11, an ulcerative colitis and Crohn's disease treatment.
EnteraSense secured $4 million (€3.5 million) in funding for its gastrointestinal tract bleed-detecting capsule, Med-Tech Innovation News reports.
Exact Sciences expects to post fourth quarter 2018 revenues between $142.5 million to $143.5 million, a 64 percent year-over-year increase.
Advertisement
Gastroenterology will have the greatest growth in the ASC marketplace over the next eight years, according to a Future Market Insights report.
Miguel Regueiro, MD, is the Cleveland Clinic's gastroenterology, hepatology and nutrition department chair.
Continental Who's Who recognized New York City-based New York-Presbyterian-Weill Cornell Medical Center's David L. Carr-Locke, MD, as a Leading Gastroenterologist of 2018-2019.
Baltimore-based Johns Hopkins researchers discovered a potential colorectal cancer biomarker.
On April 18, 1775, the shot heard round the world allegedly began the American Revolution; 87,986 days later, Miami-based Gastro Health partnered with Audax Private Equity, marking the first major PE-investment in the GI space.